CTRI/2016/04/006862暂停未知
An Open Label, Prospective, Multicentric, Non-Comparative, Single Arm Study to Evaluate the Efficacy, Safety and Tolerability of Cardoherb in the Management of Cardiac Insufficiency as a Cardio-Protective Ayurvedic Proprietary Medicine in Adult Subjects.
试验速览
- 阶段
- 未知
- 状态
- 暂停
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male and female subjects between the ages of 21 and 50 years (both ages inclusive) diagnosed with cardiac insufficiency in the last 1year.
- •2.Subjects with New York Heart Association classification of I or II.
- •3.Subjects with American Cardiology College/American heart Association classification of Stage A and B.
- •4.Echocardiogram Ejection Fraction: 35-45% at screening.
- •5.6 Minute Walk Test: Total of 300-500 metres at screening.
- •6.A minimum of one cardiovascular incident requiring medical attention or hospitalisation (less than 7 days), within 1 year prior to enrolment.
排除标准
- •1.Subjects with known or suspected allergies/hypersensitivities to herbal or Ayurvedic medicines.
- •2.Subjects with history of chronic systolic heart failure of ischemic or non-ischemic etiology at least 1 year prior to enrolment.
- •3.Subjects who have suffered a myocardial infarction, had a cardiac surgery upto 3 years prior to enrolment.
- •4.Subjects who have suffered from uncontrolled arrhythmia, stroke, renal or hepatic impairment, heart failure due to pulmonary disease at least 1 year prior to enrolment.
- •5.Subjects with untreated hypertension or diabetes mellitus for 6 months prior to enrolment.
- •6.Subjects with severe anaemia, thrombocytopenia and other haemophilic conditions that could contribute to increased cardiovascular incidents.
- •7.Subjects with pulmonary arterial hypertension, myasthenia gravis or other autoimmune diseases.
- •8.Subjects who are mentally unable to comprehend the responsibilities and adhere to the stipulations of the protocol.
- •9.Subjects who are known/reported to be pregnant, lactating, planning a pregnancy or unwilling to practice double barrier contraceptive.
- •10.Subjects who in the opinion of the investigator are deemed unfit to participate in the study.
研究者
相似试验
暂停
不适用
Clinical Study to Evaluate the Efficacy and Safety of Ayurvedic Medicine Rasnalasoona for Cervical Spondylosis in Adults.CTRI/2016/05/006954Dhathri Ayurveda Private Limited40
已完成
4 期
Study to evaluate the efficacy, safety and tolerability of fixed dose combination [FDC] Voglibose 0.3mg + Metformin (SR ) 500mg in treatment of patients with Type II diabetesCTRI/2011/06/001846Abbott Healthcare Private Limited110
已完成
不适用
Clinical study to Evaluate the Efficacy, Safety and Tolerability of an Ayurvedic Formulation in the management of Primary Dysmenorrhea in Female Adults.CTRI/2014/04/004530Ms Cavinkare Research Centre50
尚未招募
4 期
A clinical study to evaluate the safety and efficacy of Tropicamide, Phenylephrine and Lidocaine injection in patients undergoing lens replacement surgery.CTRI/2024/01/062038Appasamy Ocular Devices (P) Ltd.
尚未招募
4 期
Active PMS study to Evaluate the Safety, Tolerability and Efficacy of FDC of Epalrestat 150 mg plus Pregabalin 150 mg Bilayered Sustained Release Tablets in Adult Patients for the treatment of pain due to Diabetic Peripheral NeuropathyCTRI/2020/09/027557Aeon Formulations Pvt Ltd
